Drug profile · INN
telmisartan
APO-TELMISARTAN
telmisartan (APO-TELMISARTAN) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — telmisartan
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 4
- Programs
- 11
- Data quality
- 0.89
Quick answer
telmisartan (APO-TELMISARTAN) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 2024390317
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN
granted -
US 2024390332
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
granted -
US 11951152
Microparticle compositions for controlled delivery of telmisartan and actinomycin D
granted -
US 7501448
Process for preparing telmisartan
granted
Frequently asked questions
What is telmisartan?
telmisartan (APO-TELMISARTAN) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for telmisartan?
APO-TELMISARTAN is a marketed brand name for telmisartan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of telmisartan?
telmisartan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.